GRP Enzyme ImmunoAssay (EIA), that is specific for the mature form of GRP (amide 1–27), was purchased from Phoenix Pharmaceuticals, Inc. (Catalog # EK-027–07; Burlingame, CA). The GRP inhibitor, NSC77427, was made by the Small Molecule Library Reagent Program (National Cancer Institute, Division of Cancer Treatment & Diagnosis/Developmental Therapeutics Program, NIH). The GRP receptor antagonist, BW2258U89, was purchased from Phoenix Pharmaceuticals, Inc. (Burlingame, CA). The anti-GRP antibody mouse monoclonal antibody, MoAb 2A11 (IgG1κ), was made by the National Cancer Institute, Center for Cancer Research, NCI-Navy Medical Branch and is also specific for the mature form of GRP.6 (link) Mouse IgG1κ isotype control antibody (MOPC21) was purchased from BioLegend (San Diego, CA). Both the MOPC21 and control antibody preparations were confirmed to be endotoxin-free by a chromogenic Limulus Amoebocyte Assay (ACC, East Falmouth, MA). The murine monoclonal mAb-2A11 (2A11) was provided by Dr. Cuttitta (NCI, NIH). Rabbit polyclonal anti-PGP 9.5 was obtained from Gene Technology Co., Ltd. (Shanghai, PRC).
Bw2258u89
Manufactured by Phoenix Pharmaceuticals
Sourced in Canada
The BW2258U89 is a laboratory equipment used for the analysis and processing of biological samples. It is designed to perform specific tasks related to sample preparation, separation, and measurement. The core function of this equipment is to facilitate accurate and efficient data collection in a research or diagnostic setting. Further details about its intended use or application are not available.
Automatically generated - may contain errors
3 protocols using bw2258u89
1
GRP Enzyme Immunoassay Protocol
2
GRP Enzyme Immunoassay Protocol
3
Bombesin Receptor Selectivity Assay
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Pharmacological experiments in this study were performed on an isometric contractile apparatus. The peptides used were dissolved and prepared into stock solutions using Kreb’s solution. The fresh working solutions were prepared on the day of the experiments by diluting stock solutions using Kreb’s solution. The dose responses were then performed and recorded following applications of peptides in the range of 10−11–10−5 M to each organ bath. The changes in the muscle tone and frequency of contractions produced by the peptides could be identified through comparison with spontaneous contractions prior to peptide application.
The examination of bombesin receptor selectivity of peptides on rat urinary bladder and uterus smooth muscle was performed by using a BB1 receptor antagonist (3 × 10−7 M, BIM 23042, Tocris Bioscience, Bristol, UK) and BB2 receptor antagonist (10−6 M, BW2258U89, Phoenix Pharmaceuticals, California, United States), which were applied to tissue preparations prior to peptide treatment.
The examination of bombesin receptor selectivity of peptides on rat urinary bladder and uterus smooth muscle was performed by using a BB1 receptor antagonist (3 × 10−7 M, BIM 23042, Tocris Bioscience, Bristol, UK) and BB2 receptor antagonist (10−6 M, BW2258U89, Phoenix Pharmaceuticals, California, United States), which were applied to tissue preparations prior to peptide treatment.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!